Skip to main content

Table 4 Effect of daily home fortification with 3 mg iron as NaFeEDTA and 12.5 mg iron as encapsulated ferrous fumarate on categorical outcomes at 30 days after start of intervention, per protocol analysis

From: Daily home fortification with iron as ferrous fumarate versus NaFeEDTA: a randomised, placebo-controlled, non-inferiority trial in Kenyan children

Outcome/intervention group Prevalence (n/n) Effect (95% CI) relative to placebo
Anaemia
 Placebo 53.3% (56/105) Reference
 Iron, 3 mg as NaFeEDTA 43.7% (45/103) –9.6% (–22.7% to 3.9%)
 Iron, 12.5 mg as ferrous fumarate 51.4% (55/107) –1.9% (–15.1% to 11.3%)
Iron deficiencya
 Placebo 44.6% (25/56) Reference
 Iron, 3 mg as NaFeEDTA 24.5% (12/49) –20.2% (–36.4% to –18.5%)
 Iron, 12.5 mg as ferrous fumarate 30.5% (18/59) –14.1% (–30.7% to 3.5%)
Plasmodium infection, by dipstick testb
 Placebo 16.2% (17/105) Reference
 Iron, 3 mg as NaFeEDTA 18.4% (19/103) 2.3% (–8.1% to 12.6%)
 Iron, 12.5 mg as ferrous fumarate 22.6% (24/106) 6.4% (–4.3% to 17.0%)
P. falciparum infection, by microscopy
 Placebo 18.5% (19/103) Reference
 Iron, 3 mg as NaFeEDTA 15.5% (15/97) –3.0% (–13.4% to 7.6%)
 Iron, 12.5 mg as ferrous fumarate 15.2% (15/99) –3.3% (–13.6% to 7.2%)
  1. aAnalysis restricted to children without inflammation (see text)
  2. bPresence of HRP, pLDH specific to P. falciparum or pLDH due to human Plasmodium species other than P. falciparum